glp 1 dpp 4 DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits Cardiovascular effects of DPP-4 inhibition:
Description
Both medications are GLP-1 agonists used primarily for managing type 2 diabetes and aiding in weight loss
Hers, H
doi: 10.1055/s-0035-1555791
As of February 15, 2026, GHK-Cu remains classified primarily as a cosmetic ingredient rather than an FDA-approved drug
Health Improvements: Beyond weight loss, semaglutide can contribute to improvements in obesity-related conditions
Vitam Horm, 74:443-477
